{
    "2019-09-05": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Special Situations Gurus Are Buying",
                "features": {
                    "keywords": [
                        "Gurus",
                        "Buying",
                        "Special Situations"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "J&J's Stelara Gets Approval in EU for Ulcerative Colitis",
                "features": {
                    "keywords": [
                        "J&J",
                        "Stelara",
                        "Approval",
                        "EU",
                        "Ulcerative Colitis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "5 Dividend Aristocrats Where Analysts See Capital Gains",
                "features": {
                    "keywords": [
                        "Dividend Aristocrats",
                        "Capital Gains",
                        "Analysts"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "dividends"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "Can Biosimilars Take On $198 Billion In Blockbuster Drug Sales?",
                "features": {
                    "keywords": [
                        "Biosimilars",
                        "Blockbuster Drug Sales",
                        "$198 Billion"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}